A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Relapsed or Refractory Hairy Cell Leukemia (HCL).

Trial Profile

A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Relapsed or Refractory Hairy Cell Leukemia (HCL).

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Dec 2017

At a glance

  • Drugs Moxetumomab pasudotox (Primary)
  • Indications Hairy cell leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors MedImmune
  • Most Recent Events

    • 06 Dec 2017 Data from this trial will be presented at the 59th 2017 American Society of Hematology (ASH) Annual Meeting & Exhibition, according to an AstraZeneca media release.
    • 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 09 Jul 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top